Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men

Autor: Joseph Olivieri, Donald Gardenier, Robert Cohen, Jose Lares-Guia, Richie Tran, Lembitu Sorra, Robert Chavez, Punyadech Photangtham, Daniel S. Fierer, Livette Johnson, Paul C. Bellman, Rona Vail, Randy Levine, Patrick Dalton, Rita Chow, Oscar Klein, Alicia Stivala, Donald Kaminsky, Douglas T. Dieterich, Anita Radix, William Shay, Gal Mayer, Susanne Burger, Gabriela Rodriguez-Caprio, Ward Carpenter, Erik Mortensen, Krisczar Bungay, Michel Ng, Ricky Hsu, Susan Weiss, Terry Farrow, Martin Markowitz, Nirupama Somasundaram, Melissa Wiener, William Mandell, Francis Wallach, Michael P. Mullen, Daniel Bowers, John Dellosso, Adrian Demidont, Wouter O. van Seggelen, Eddie Meraz, Eric Leach, Juan Bailey, Stuart Haber, Charles Paolino, Rosanne M. Hijdra, Amisha Malhotra, SI Rapaport, Lawrence Hitzeman, Antonio Urbina, Sneha Jacob, Alison J. Uriel, Andrea D. Branch, Jeffrey C. Kwong, Rodolfo Guadron, Larisa Litvinova, Eileen Donlon, Wen Wang, Lawrence Higgins, Victor Inada, Damaris C. Carriero, Barbara Johnston, Bisher Akil, Stephen Dillon, Shirish Huprikar, David G. Cassagnol, George Psevdos, Irina Linetskaya

Publikováno v: Clinical Infectious Diseases. 58:873-879

(See the Editorial Commentary by Zeremski et al on pages 880–2.) Hepatitis C virus (HCV) chronically infects an estimated 5.2 million people in the United States and 170 million people worldwide [1]. However, as most initial (“acute”) infection

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3354c7a784d358145bd551d713f65ba4
https://doi.org/10.1093/cid/cit799